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ABSTRACT Pyrazinamide (PZA) is considered the pivot drug in all tuberculosis
treatment regimens due to its particular action on the persistent forms of Mycobac-
terium tuberculosis. However, no drug susceptibility test (DST) is considered suffi-
ciently reliable for routine application. Although molecular tests are endorsed, their
application is limited to known PZA resistance associated mutations. Microbiological
DSTs for PZA have been restricted by technical limitations, especially the necessity
for an acidic pH. Here, for the first time, MODS culture at neutral pH was evaluated
using high PZA concentrations (400 and 800 g/ml) to determine PZA susceptibility
directly from sputum samples. Sputum samples were cultured with PZA for up to
21 days at 37°C. Plate reading was performed at two time points: R1 (mean, 10 days)
and R2 (mean, 13 days) for each PZA concentration. A consensus reference test,
composed of MGIT-PZA, pncA sequencing, and the classic Wayne test, was used. A
total of 182 samples were evaluated. The sensitivity and specificity for 400 g/ml
ranged from 76.9 to 89.7 and from 93.0 to 97.9%, respectively, and for 800 g/ml
ranged from 71.8 to 82.1 and from 95.8 to 98.6%, respectively. Compared to MGIT-
PZA, our test showed a similar turnaround time (medians of 10 and 12 days for PZA-
sensitive and -resistant isolates, respectively). In conclusion, MODS-PZA is presented
as a fast, simple, and low-cost DST that could complement the MODS assay to eval-
uate resistance to the principal first-line antituberculosis drugs. Further optimization
of test conditions would be useful in order to increase its performance.
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According to the World Health Organization (WHO), tuberculosis (TB) is one of thetop ten causes of death worldwide and the most important cause by a single
infectious agent (1). In 2017 there were 10 million new cases of disease caused by
Mycobacterium tuberculosis and over 1.3 million deaths (1). Currently, drug resistance is
the main factor that impedes TB eradication initiatives. The capacity to detect drug-
resistant TB remains limited in low- and middle-income countries, where it is most
needed (2). Discovered in 1953, pyrazinamide (PZA) has proven to be an indispensable
first-line anti-TB agent (3–5) which, unlike other first-line agents, exhibits a unique
sterilizing ability, inhibiting slowly metabolizing or nonmetabolizing bacilli (6, 7). Its
inclusion in treatment regimens enabled them to be shortened from 9 to 6 months (8).
Despite this, its mechanism of action remains poorly understood (9). It has been
shown that PZA is converted to its active component, pyrazinoic acid (POA), by the
pyrazinamidase enzyme (PZAse) in the intracellular environment of M. tuberculosis. It is
accepted that POA causes cytoplasmic acidification and disruption of membrane
potential (10–12) and possibly interacts with a range of intracellular targets (7, 13).
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Mutations in pncA, the gene encoding PZAse, have been reported as the primary cause
of PZA resistance (7, 14). It has been estimated that between 40 and 80% of multidrug-
resistant TB (MDR-TB) and 100% of extensively drug-resistant TB (XDR-TB) strains have
also been reported as resistant to PZA (5, 15–17). Even though PZA is considered the
only first-line drug to be preserved in all future treatment regimens (18–21), PZA DST
is not routinely performed and is seldom used to plan a personalized treatment
regimen (9).
The development of molecular diagnostic tests to detect PZA resistance have been
limited due to the large number of mutations along the pncA gene (14), the lack of a
mutation hot spot, and the fact that not all mutations cause PZAse impairment or have
been associated with a specific PZA susceptibility phenotype (15, 22–25). However,
recently some genotypic DST have been reported with considerable sensitivity and
specificity, such the Genoscholar PZA-TB II LPA (Nipro Corporation, Japan), which is a
line probe assay (LPA), and a high-resolution melting assay. Previous studies have
reported an agreement of 97.6% between the PZA-TB II LPA and a composite reference
(pncA sequencing plus phenotypic DST) when heteroresistance is excluded (26), and a
sensitivity of 93.2% and a specificity of 91.2% when the test was compared to only pncA
sequencing (27). On the other hand, the high-resolution melting assay has been
described as having an agreement of 94 and 84% with pncA sequencing and MGIT-PZA,
respectively (28). Nonetheless, one limitation for the immediate application of these
tests is that the genetic diversity of pncA mutations can vary appreciably between
different geographical regions, affecting the sensitivity and specificity of the test (26,
27). As a matter of fact, the correlation between pncA sequencing and detection of
mutations with PZA resistance varies among countries low and high endemicities, with
reported estimates of 41% in Taiwan, 67% in South Africa, 72 to 84% in Brazil, 91% in
China, and 97% in China and Japan (7, 18).
There is currently no WHO-endorsed phenotypic drug susceptibility test (DST) for
detecting PZA resistance due to various technical limitations affecting the utility of
currently available assays. These limitations include long turnaround times, poor re-
producibility, requirements for an acidic pH, and medium alkalization due to inoculum
size (9, 15, 29, 30). Performing direct phenotypic DST for PZA has been hampered by
the difficulty in demonstrating anti-TB activity of the drug when analyzed under
conventional culture conditions. The widely accepted explanation for this is the re-
quirement of an acidic environment for PZA to exert anti-TB activity versus the pH close
to neutral of the culture medium (9, 10, 18, 31–33). At present, the Bactec MGIT 960 PZA
(MGIT-PZA) assay is the accepted standardized phenotypic DST (34). However, several
publications have reported a high rate of false PZA resistance and poor reproducibility,
both drawbacks related to pH variation produced by the inoculum size used in the
assay (35–39).
The microscopic observation drug susceptibility (MODS) assay is a relatively rapid
and inexpensive direct drug susceptibility test used in the diagnosis of TB and MDR-TB
(40–42) and XDR-TB (43–45). Previous studies have evaluated the use of MODS culture
for analysis of PZA resistance using PZA concentrations ranging between 6.25 and
3,200 g/ml (46–48). These studies have compared MODS for PZA susceptibility deter-
mination against the MGIT-PZA (46), the proportion method (47), and the absolute
concentration method (48), reporting sensitivity and specificity ranges of 95.5 to 100%
and 93.3 to 100%, respectively. In all cases, a high concordance between MODS and the
selected reference method was observed, although all tests were performed with
cultured M. tuberculosis strains and not directly from clinical sputum samples.
In the present study, for the first time, we evaluated the use of MODS to determine
PZA resistance directly from sputum samples. MODS-PZA is a test that was conceived
as a complement for the traditional MODS test to determine resistance to all the
first-line antituberculosis drugs. MODS-PZA has been standardized based on the fact
that several studies have reported that stress factors can strengthen PZA activity even
in nonacidic media (6, 9, 31, 49–51). These stress factors must affect the metabolism of
M. tuberculosis in order to predispose the mycobacteria to show a PZA-sensitive
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phenotype (9). This is in keeping with observations that PZA performs better against M.
tuberculosis bacilli with a reduced metabolic rate compared to those in log-phase
growth (6, 49). Therefore, for this study, it was assumed that the normal decontami-
nation step might produce a degree of stress that can nonspecifically reduce the
mycobacterial metabolic rate. We performed MODS culture directly from sputum
samples using high drug concentrations (400 and 800 g/ml) and a pH close to neutral
(pH 6.8). These results are compared to a consensus reference test based on three tests:
MGIT-PZA, the classical Wayne test, and pncA sequencing.
MATERIALS AND METHODS
Sample selection. Sputum samples were obtained from patients enrolled in the TB programs at the
Hospital Cayetano Heredia and Hospital Nacional Dos de Mayo, both in Lima, Peru, and the Regional
Tuberculosis Reference Laboratory (Callao Reference Laboratory), Callao, Lima, Peru. All selected samples
had a minimum volume of 2 ml and were determined to be positive for M. tuberculosis by MODS culture.
Since an estimated prevalence of 50% of PZA resistance has been reported for MDR-TB strains (5, 15), ca.
50% of the selected samples were MDR-TB or monoresistant to isoniazid (INH) or rifampin (RIF) and 50%
were INH and RIF susceptible in order to obtain an adequate number of PZA-resistant strains. Data
regarding sex, age, and TB treatment were collected when available. Ethical approval was obtained from
the ethical committee from the Universidad Peruana Cayetano Heredia (IRB 418-20-15).
MODS for M. tuberculosis identification and MDR-TB detection. Sputum samples (2 ml) were
decontaminated according to the standardized MODS protocol (52). Briefly, the sputum sample was
mixed with 2 ml of NaCl-NaOH and incubated for 15 min at room temperature. Phosphate buffer (pH 6.8)
was then added to neutralize the sample, which was then centrifuged for 15 min at 3,000 g. The
decontaminated pellets were resuspended in 6 ml of Middlebrook 7H9 (Fisher Scientific) medium
enriched with oleic acid-albumin-dextrose-catalase (OADC) and polymyxin B, amphotericin B, nalidixic
acid, trimethoprim, and azlocillin (PANTA). MODS testing was performed in 24-well plates according to
the standardized MODS protocol (52). Briefly, 100 l of 7H9 medium was dispensed into the first and
second wells (growth control wells), and 100 l of drug suspension (final concentrations, INH at 4 g/ml
and RIF at 10 g/ml) was added to the third and fourth wells, respectively (drug susceptibility wells).
Next, 900 l of the resuspended pellet was dispensed into these four wells to make a total volume of
1 ml. The plate was incubated at 37°C for a maximum of 21 days. A plate reading was performed using
an inverted microscope at 100 total magnification in order to observe the cording growth of M.
tuberculosis (52). Both control wells were evaluated at day 5 and then every other day. Positive growth
was reported when at least two CFU were observed. Drug susceptibility wells (INH and RIF) were
evaluated at the time that growth was observed in both control wells. Drug resistance was reported
when positive growth was observed in these wells.
MODS for PZA susceptibility determination (MODS-PZA). The goal of sample decontamination
prior to culture is to drastically reduce the number of viable contaminants, but the reagents used in this
process also affect the viability of M. tuberculosis (53–56). Therefore, we hypothesized that the decon-
tamination step could produce some degree of stress that permits PZA to work. Consequently, MODS-
PZA (MODS for PZA susceptibility determination) was standardized to determine PZA susceptibility using
7H9 medium enriched with OADC-PANTA directly from sputum samples at a pH close to neutral.
From each decontaminated sample, 900 l was inoculated into the fifth and sixth wells of the same
culture plate for MDR detection. Next, 100 l of 4,000 and 8,000 g/ml PZA was added to the fifth and
the sixth wells (PZA wells), respectively (Fig. 1). The plate was read as previously mentioned for MDR-TB
detection (first plate reading [R1]). PZA resistance was reported when a growth level similar to that in the
control well was observed (Fig. 2A). Alternatively, PZA susceptibility was reported when no growth or a
lower growth level than in the control well was detected (Fig. 2B). Samples that did not show any growth
were incubated for 21 days and evaluated every other day. A second plate reading (R2) was reported if
growth was observed before 21 days of culture, following the previous criteria to determine PZA
susceptibility.
Consensus reference test for PZA susceptibility determination. Currently, there is no single test
that is recognized as a reference method to determine PZA susceptibility. Consensus reference standards
have been reported as an option for evaluating drug susceptibility when no other reference method is
available (57). In this study, Bactec MGIT 960 PZA (MGIT-PZA), the classic Wayne assay, and pncA
sequencing to detect nonsynonymous mutations were combined into a consensus reference test (CRT).
PZA susceptibility was reported when a susceptible result was obtained in at least two of the three
methods; conversely, PZA resistance was reported when a resistant result was observed in at least two
of the three methods. To perform the test, pure M. tuberculosis isolates were obtained by culturing an
aliquot of 100 l from one of the control wells on plates containing 7H11 medium (Fisher Scientific)
enriched with OADC. The plates were incubated at 37°C for 3 weeks (maximum, 21 days).
For MGIT-PZA, an M. tuberculosis suspension with a turbidity of 0.5 McFarland was prepared using
physiological saline. The suspension was diluted to 1:5 and 1:10, and 0.5-ml portions of each dilution
were inoculated into the test and the control tubes, respectively. PZA was added to the test tube to a
final concentration of 100 g/ml. The tubes were incubated in a MGIT 960 system. PZA susceptibility was
determined by comparing the fluorescent signal between the control and the test tube over a period of
4 to 21 days.
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For pncA sequencing, one full loop of a 21-day M. tuberculosis culture was suspended in 100 mM
Tris-EDTA buffer (pH 8.0). The suspension was inactivated by heating to 80°C for 30 min, and genomic
DNA was extracted after a modified proteinase K-chloroform protocol (58). Briefly, 100 l of 10 mg/ml of
lysozyme was added, and the sample was incubated overnight at 37°C in agitation. The following day for
sample digestion, 20 mg/ml of proteinase K and 10% sodium dodecyl sulfate was added, and the sample
was incubated at 65°C for 3 h. After that, 5 M NaCl–10% CTAB (cetyltrimethylammonium bromide) was
added, and the sample was incubated at 65°C for another 15 min. Then, a solution of phenol-chloroform-
isoamilic alcohol (25:24:1) was added in equal volumes, and this was mixed gently. The sample was
centrifuged at 10,000 rpm at 4°C for 10 min. The upper layer was transferred to a new tube, and
FIG 1 MODS-PZA plate setting. Four samples were evaluated in each plate. Two control wells were
included for each sample.
FIG 2 MODS-PZA results. PZA susceptibility determination was performed by inverted microscopy.
Both control and drug wells were evaluated. (A) PZA-resistant isolate. Bacterial growth is observed
in both control and PZA wells. (B) PZA-susceptible isolate. Bacterial growth is strongly differentiated
between control and PZA wells.
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phenol-chloroform was added (1:1). The sample was centrifuged at 10,000 rpm at 4°C for 10 min. This
step was repeated. To precipitate the DNA, 95% ethanol was added, and the sample was incubated at
–80°C for 30 min. The sample was centrifuged at 10,000 rpm at 4°C for 10 min, and a wash step was
performed with 70% ethanol; the pellet was then dried at room temperature. For resuspension, 50 l of
Tris-EDTA buffer (pH 8.0) was added. PCR was performed using the primers P1 (5=-GTCGGTCATGTTCGC
ATCG-3=; from 105 bp upstream of pncA) and P6 (5=-GCTTTGCGGCGAGCGCTCCCA-3=; from 60 bp
downstream of pncA) (59). The PCR cycling parameters were as follows: one cycle of 94°C for 4 min;
followed by 30 cycles of 94°C for 45 s, 58°C for 60 s, and 72°C for 60 s; with a final step of 94°C for 5 min.
The PCR product length was 720 bp. Sequencing was performed using the same pair of primers. The M.
tuberculosis H37Rv reference strain (NC_000962.3) was used as a reference for the pairwise sequence
alignment in order to detect mutations in the pncA gene and its putative promoter. PZA susceptibility
for the mutations detected was assigned according to the Tuberculosis Drug Resistance Mutation
Database (60).
The classic Wayne test was performed as previously described (61). Briefly, three full loops of M.
tuberculosis 21-day culture were inoculated in tubes containing Dubos medium, followed by incubation
at 37°C for 7 days. Positive (H37Rv) and negative (DM097) controls were included. At day 7, 1 ml of 1%
ferrous ammonium sulfate (SAF; Sigma-Aldrich) was added. After 5 min of incubation at room temper-
ature, each tube was read. A positive result (i.e., a PZA-susceptible strain) was reported when a pink band
was observed at the top of the media. In contrast, a negative result (i.e., a PZA-resistant strain) was
reported when there was an absence of the pink band.
Data analysis. The sensitivity and specificity (95% CI) of MODS-PZA was calculated by comparison
with the CRT in a 2 2 contingency table for each PZA concentration and plate reading day. McNemar’s
test was used to determine significant differences between the sensitivities and specificities calculated.
The Fisher exact test was used to determine the association between growth level in culture and the
determined PZA susceptibility. Agreement between the dichotomous MODS-PZA, the CRT, and MGIT-
PZA was estimated by using the kappa statistic. All statistical tests were reported with 5% significance
using STATA v14.0.
RESULTS
Study population. A total of 183 sputum samples were collected. One was ex-
cluded from the analysis due to inconsistent results. Of the remaining 182 samples,
51.1% (93/182) were reported as RIF and INH susceptible, 30.22% (55/182) were MDR-TB
(i.e., resistant to both RIF and INH), 12.09% (22/182) were monoresistant to INH, and
6.59% (12/182) were monoresistant to RIF. Data regarding patient age and sex, site of
sample collection, tuberculosis treatment, and sputum acid-fast microscopy results are
presented in Table 1.
Consensus reference test for PZA susceptibility determination. According to
the CRT, 78.57% (143/182) of the samples were reported as PZA susceptible, and
21.43% (39/182) were reported as PZA resistant. A total of 50.91% (28/55) of the
MDR-TB samples and 58.33% (7/12) of the RIF monoresistant samples were PZA
resistant (Table 2).
According to MGIT-PZA, 75.27% (137/182) of the samples were reported as PZA
susceptible, and 24.73% (45/182) as PZA resistant. Six samples did not agree with the
CRT. Four of these discordant samples had the K48T and F81S pncA mutations, which
have been reported as showing a PZA-resistant phenotype by MGIT-PZA when this
method was performed using 100 g/ml of PZA. However, a higher critical concentra-
tion of PZA (300 g/ml) classified these isolates as PZA susceptible (data not shown) in
concordance with the classical Wayne test and pncA sequencing. The other two
presented a wild-type genotype.
According to the classic Wayne test, 83.52% (152/182) of the samples were PZA
susceptible and 16.48% (30/182) were PZA resistant. Nine samples showed discordancy
with the CRT; all nine samples had mutations detected in the pncA gene (H51R, Q10P,
and Q10R).
Finally, by pncA sequencing, 26.92% (49/182) of the samples reported a nonsyn-
onymous pncA mutation (i.e., in its putative promoter or in the gene itself), and 73.08%
(133/182) displayed the wild-type genotype. Q10R was the most frequently observed
mutation (28.57%), followed by H51R (18.37%), and K48T (16.33%). All other reported
mutations were found in fewer than five samples, including one sample with the A-11C
(nucleotide) mutation in the pncA promoter (Table 3). The P62S, K48T, and F81S
mutations (i.e., observed in this study) were linked to a PZA-susceptible phenotype
according to the Tuberculosis Drug Resistance Mutation Database (54). Overall, 79.12%
(144/182) and 20.88% (38/182) of samples were reported as PZA susceptible and
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resistant, respectively. Just one sample was discordant with the CRT, in which pncA
sequencing did not report any mutations, but both MGIT-PZA and the classic Wayne
test were reported as showing PZA resistance (see Table S1 in the supplemental
material).
Growth level in culture. M. tuberculosis culture growth was classified into four
growth levels: high, regular, low, and microcolonies only. Ninety-three percent of the
samples reported at least a low level of growth in culture, including 94.4% of the
PZA-sensitive isolates (determined by the CRT) and 89.74% of the PZA-resistant isolates
(Table 4). No significant association (P  0.107) was found between the level of growth
on culture and PZA susceptibility, as determined by CRT.
MODS-PZA performance. A similar percentage of PZA-susceptible and -resistant
samples was observed in both PZA wells (400 and 800 g/ml) at the first plate reading
(R1). Twelve samples showed a conversion to PZA resistance at 400 g/ml PZA for the
second plate reading (R2), and eight samples showed a conversion to PZA resistance at
800 g/ml. For R1, three samples showed discordant results at between 400 and
800 g/ml PZA. One of these samples presented a wild-type genotype and was
TABLE 1 Study population characteristicsa
Variable No. (%)
Collection center
Callao Reference Laboratory 140 (76.9)
Hospital Cayetano Heredia 11 (6.0)
Hospital Dos de Mayo 31 (17.0)
Age (yr)
30 54 (29.7)
30–60 66 (36.3)
60 62 (34.1)
Sex
Female 52 (28.6)
Male 108 (59.3)
Data not available 22 (12.1)
TB treatment
Previous or ongoing treatment 83 (45.6)
Never treated 19 (10.4)
Data not available 80 (43.9)
Sputum acid-fast microscopy resultb
Negative 11 (6.0)
Paucibacillary 10 (5.5)
1 38 (20.9)
2 58 (31.9)
3 65 (35.7)
aAll samples were selected according to the following criteria: a minimum sample volume of 2 ml and a
positive sputum acid-fast smear microscopy result (health center results).
bPaucibacillary, 1 to 9 bacilli in 100 fields; 1, 10 to 99 bacilli in 100 fields; 2, 1 to 10 bacilli per field in 50
fields; 3, 10 bacilli per field in 20 fields.
TABLE 2 Sample distribution according to its PZA and TB resistance profilea
PZA susceptibilityb
No. (%) with TB various resistance profilesc
Total no. (%) of samplesMDR-TB RIFr INHr RIFs and INHs
PZA susceptible 27 (49.09) 5 (41.67) 21 (95.45) 90 (96.77) 143 (78.57)
PZA resistant 28 (50.91) 7 (58.33) 1 (4.55) 3 (3.23) 39 (21.43)
aResults were determined by a consensus reference test (CRT), comprising MGIT, Wayne assay, and pncA
sequencing, and MODS culture, respectively. PZA susceptibility is displayed according to the TB
susceptibility profile.
bAs determined by a CRT.
cRIFr, RIF (rifampin) monoresistant; INHr, isoniazid (INH) monoresistant; RIFs, RIF susceptible; INHs, INH
susceptible.
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determined to be PZA susceptible by the CRT. The remaining two samples were PZA
resistant, with nucleotide deletions in the pncA gene. Likewise, for R2 seven samples
showed discordant results. Three samples were determined to be PZA resistant by the
CRT, and all of these had the Q10R mutation and a deletion in the pncA gene. The other
four samples were determined to be PZA susceptible according to the CRT, and just one
had the F81S mutation. No significant association was observed between PZA suscep-
tibility determined in R1 and the level of growth using either 400 g/ml (P  0.069) or
800 g/ml (P  0.064) PZA. However, a significant association was reported for PZA
susceptibility in R2 at both 400 g/ml and 800 g/ml PZA (P  0.045 and P  0.021,
respectively). Although not significant, an association was observed for R1 at both
concentrations, with a tendency toward an increase (approximately 40 to 50%) for a
high growth level for PZA-resistant isolates from R1 to R2 in both concentrations. This
event did not occur for PZA-susceptible isolates, for which the high growth level
percentage was around 50% at both R1 and R2. The percentages for the other growth
levels did not show any changes from R1 to R2 (data not shown).
Accuracy measures for MODS-PZA. Results obtained at each PZA concentration
and reading day were compared independently to the CRT in order to evaluate
sensitivity and specificity. For both drug concentrations, the sensitivity and specificity
were 70 and 90%, respectively (Table 5). When using a PZA concentration of
400 g/ml, a significant difference was observed between R1 and R2 in specificity (P 
0.016) but not in their sensitivity (P  0.063). On the other hand, no significant
TABLE 3 pncA mutations reported in this studya
Genotype
No. (%) of
isolatesb
PZA susceptibility
(database/literature)c
PZA susceptibility
(CRT)d
D49N 1 (0.55) Resistant Resistant
D8E 2 (1.10) Resistant Resistant
F81S 2 (1.10) Susceptible Susceptible
H51R 9 (4.95) Resistant Resistant
H57L 1 (0.55) Resistant Resistant
H71R 2 (1.10) Resistant Resistant
I6S 2 (1.10) Resistant Resistant
K48T 8 (4.40) Susceptible Susceptible
P62S 1 (0.55) Susceptible Susceptible
A-11G 1 (0.55) Resistant Resistant
Q10P 2 (1.10) Resistant Resistant
Q10R 14 (7.69) Resistant Resistant
Δ375–389 1 (0.55) Resistant Resistant
Δ456–466 3 (1.65) Resistant Resistant
Wild type 133 (73.08) Susceptible Susceptible
aMutations observed among the putative promoter and pncA gene are shown, along with their
corresponding PZA susceptibility phenotype, as defined by both the Tuberculosis Drug Resistance Mutation
Database and our consensus reference test (CRT).
bThe percentage was calculated based on the total number of samples (n 182).
cAccording to the Tuberculosis Drug Resistance Mutation Database and the literature.
dAs determined by CRT (MGIT, Wayne assay, and pncA sequencing).
TABLE 4 Level of mycobacterial growth in the control well of the MODS-PZA reported by
PZA susceptible profilea
PZA susceptibilityb
Growth level expressed as no. (%) in control wells in a MODS-PZA
assay
Microcolonies Low Regular High Total
Susceptible 8 (5.59) 13 (9.09) 50 (34.97) 72 (50.35) 143 (100)
Resistant 4 (10.26) 8 (20.51) 9 (23.08) 18 (46.15) 39 (100)
Total 12 (6.59) 21 (11.54) 59 (32.42) 90 (49.45) 182 (100)
aFour levels of growth were determined according to microscopic evaluation: “Microcolonies” indicates fewer
than 20 microcolonies in the well, “low” refers to a barely covered well, “regular” indicates half of the well
was covered, and “high” indicates a completely covered well. No significant association (P  0.05) was
found between PZA susceptibility and the level of growth.
bAs determined by CRT.
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difference in sensitivity or specificity was observed when using PZA concentrations of
800 g/ml between R1 and R2 (both P  0.125). In addition, no significant difference
was observed in sensitivity and specificity between 400 and 800 g/ml of PZA in R1
(P  0.5 and P  1.0, respectively) and in R2 (P  0.25 and P  0.125, respectively). A
kappa index and agreement percentage of 0.79 and 93.41%, respectively, were re-
ported for a PZA concentration of 400 g/ml, and 0.77 and 92.86%, respectively, for a
PZA concentration of 800 g/ml; both in R1. Similarly, in R2 a kappa index and
agreement percentage of 0.78 and 92.31%, respectively, were reported for 400 g/ml
PZA, and 0.79 and 92.86%, respectively, for 800 g/ml PZA.
From the samples that had discordant results for MODS-PZA at 400 g/ml PZA and
the CRT, those that were reported as PZA resistant by MODS-PZA but PZA susceptible
by the CRT showed either a wild-type genotype or the P62S or F81S mutations in the
pncA gene. However, these mutations have been previously reported in the PZA-
resistant phenotype associated with mutations represented in a M. tuberculosis mutant
pncA library, where the PZA susceptibility was detected by MGIT 960 and bioinformatics
prediction (62). On the other hand, samples that were reported to be PZA susceptible
by MODS-PZA but PZA resistant by CRT had Q10R, Q10P, H51R, H71R, and A-11C
mutations detected in the pncA gene and its putative promoter. All of these mutations
have been reported to confer PZA resistance with high confidence (60, 63). No
differences between bacillary load (i.e., by sputum acid-fast smear or level of growth in
culture) were observed (data not shown). The same results were observed for isolates
with discordancy between MODS-PZA performed at 800 g/ml PZA and the CRT,
including samples in which pncA deletions (nucleotide deletions Δ375–389 and Δ456–
466) were detected and yet were reported as PZA susceptible in 800 g/ml of PZA.
MODS-PZA was compared to MGIT-PZA since both tests are based on the principle
that culture in the presence of the drug would inhibit bacterial growth. A kappa index
of 0.74 and an agreement percentage of 91.21% were found for 400 g/ml at R1, a
kappa index of 0.72 and agreement of 90.66% were found for 800 g/ml at R1, a kappa
index of 0.79 and agreement of 92.31% for 400 g/ml were found at R2, and finally a
kappa index of 0.77 and an agreement of 91.76% for 800 g/ml were found at R2. The
median turnaround time for MODS-PZA was 10 days (range, 5 to 24 days) for R1, and
the R2 was performed a median of 3.1 days after R1.
DISCUSSION
This study reports, for the first time, the application of MODS culture to determine
PZA resistance directly from sputum culture through the evaluation of PZA activity at
neutral pH (MODS-PZA). Unlike other studies that have evaluated the application of
MODS for PZA resistance determination in M. tuberculosis strains (46–48), our findings
have demonstrated the possibility of directly evaluating sputum samples with high PZA
concentration (400 and 800 g/ml) without the need for additional processing except
for a decontamination step. Including PZA in the spectrum of M. tuberculosis drugs that
are currently tested in MODS (RIF, INH, and second-line drugs) (41–43, 64) will give a
complete drug susceptibility test that could be applied routinely in low-income coun-
tries.
The principal limitation for traditional phenotypic DST for PZA susceptibility deter-
TABLE 5MODS-PZA performance was evaluated against the consensus reference testa
PZA dose (g/ml) Plate reading day
Sensitivity Specificity
Kappa index Agreement (%)% (n/N) 95% CI % (n/N) 95% CI
400 R1 76.9 (30/39) 0.61–0.89 97.9 (140/143) 0.94–0.99 0.79 93.4
R2 89.7 (35/39) 0.76–0.97 93.0 (133/143) 0.88–97.00 0.78 92.3
800 R1 71.8 (28/39) 0.55–0.85 98.6 (141/143) 0.95–0.99 0.77 92.8
R2 82.1 (32/39) 0.66–0.92 95.8 (137/143) 0.91–0.99 0.79 92.9
aEach accuracy measurement was calculated with a 95% confidence interval (95% CI). R1, first plate reading; R2, second plate reading. n/N, number positive/total
number tested.
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mination has been the requirement of an acidic pH in order to allow PZA to show
antituberculosis activity (15, 29, 30). In vivo, a concentration peak in blood between 20
and 60 g/ml (1 to 2 h postdose) is active against M. tuberculosis (65). These concen-
trations are active during the early phase of infection because the physiological pH is
reduced due to ongoing inflammatory processes. According to the proposed mecha-
nism of action for PZA, when POA is released in an acidic medium (pH 5.5), some
molecules are protonated (due to its pKa of 2.9) and reenter the cytoplasm, showing its
bactericidal effect (66). In vitro, a similar condition can be obtained when the culture is
performed at pH 5.5 (using an MIC of 50 g/ml). However, an acidic pH has been
reported to inhibit M. tuberculosis growth (30, 31). Theoretically, higher concentrations
of PZA can show antituberculosis activity at a higher pH. Therefore, an active PZA
concentration can be estimated for a particular pH using the Henderson-Hasselbach
equation (67). One disadvantage of this methodology is that susceptibility results of
DST using higher drug concentrations cannot be directly related to pharmacokinetic
parameters determined in vivo. However, it should be considered that the objective of
any DST is the discrimination between susceptible and resistant strains. For this study,
PZA concentrations of 400 and 800 g/ml were selected to evaluate PZA susceptibility
based on the expected active PZA concentration for a pH of 6.8 (estimated concen-
tration, 992 g/ml) and some past studies that reported a PZA activity of 300 to
400 g/ml in 7H12 broth at pH 6.0 to 6.2 (68–70).
Even though no significant differences were reported between the sensitivities of
the two reading time points (R1 and R2) in this study (P  0.05), reported that
sensitivities were lower than those shown in other studies. All other studies (46–48)
have reported a sensitivity close to 95% but used 100 g/ml PZA as the critical
concentration and at a lower pH (6.0); although these studies evaluated higher con-
centrations of PZA, ranging from 6.25 to 3,200 g/ml, 100 g/ml was used as the cutoff
for sensitivity determination. However, this concentration has been shown to lead to
the false reporting of isolates as resistant (36, 39, 68) since it is lower than the expected
PZA concentration for pH 6.0. It is important to bear in mind that none of those studies
used a CRT as a gold standard: they compared MODS for PZA against MGIT-PZA (46),
the broth microdilution method (47), and the proportion method (48).
Another important difference that may account for the observed sensitivity variation
is that those studies used a McFarland dilution of M. tuberculosis strains previously
isolated in Lowenstein-Jensen medium as the inoculum, rather than direct inoculation
of sputum samples. This could therefore indicate that a larger number of viable
mycobacteria were evaluated than would be found in clinical samples. The specificity,
which ranged from 93.0 to 98.6%, was similar to that reported in other studies close to
95% (46, 48); Ghiraldi et al. (47) reported a sensitivity of 100%, but the number of
PZA-resistant strains included in that study was small (n 8).
Discordant samples that were reported as PZA sensitive by MODS-PZA but PZA
resistant by CRT showed mutations in the pncA gene or the putative promoter,
independently of the concentration of PZA. The mutations observed in these isolates
were H51R, H71R, Q10P, Q10R, A-11C, Δ375–389, and Δ456–466. All of these mutations
have been strongly associated with PZA-resistant phenotypes (11, 22, 25, 63). These
mutations affect the catalytic site or the metal-binding site of PZAse, eliminating its
enzymatic activity (11, 22, 63). Almost all of these isolates were MDR-TB or monoresis-
tant to RIF (88.89% for 400 g/ml and 90.91% for 800 g/ml PZA in R1 and 100% for
both 400 and 800 g/ml PZA in R2) and demonstrated at least a low level of growth in
control wells. On the other hand, discordant samples that were reported as PZA
resistant by MODS-PZA but PZA sensitive by CRT showed a wild-type genotype or
carried the F81S or P62S mutations, which are reported as being associated with
PZA-sensitive phenotypes in the Tuberculosis Drug Resistance Mutation Database (60).
These isolates were MDR-TB, monoresistant to INH, or non-MDR-TB. The growth level in
culture did not show the same tendency as the previously described discordant
samples: these samples were reported as either microcolonies only or having a high
growth level. Although no plausible explanation was found for these observations,
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some similar discordances have been reported elsewhere (48). PZA-sensitive strains
with a wild-type genotype that were reported as PZA resistant by MODS showed a
PZA-sensitive phenotype by the proportion method in Lowenstein-Jensen medium,
with an MIC ranging from 600 to 1,200 g/ml. Likewise, a PZA-sensitive strain with the
L35P mutation (associated with a PZA-sensitive phenotype) was reported as PZA
resistant in MODS with an MIC of 1,200 g/ml PZA.
Upon comparison to MGIT-PZA, since both assays have the same rationale, the test
showed a sensitivities ranging from 68.9 to 84.4% for R1 and from 64.4 to 75.6% for R2
for 400 and 800 g/ml PZA, respectively. The specificity fell within a narrower range of
94.9 to 98.7%, with an agreement close to 91.0%. However, it must be noted that
MGIT-PZA is performed with M. tuberculosis cultures. A previous study (71) that eval-
uated the performance of MGIT-PZA directly from sputum samples reported uninter-
pretable results for 163 samples, varying from 23 to 66% among all of the participating
laboratories. Moreover, the percentage of successful MGIT-PZA procedures performed
directly from sputum samples compared to traditional MGIT-PZA was 59% (range, 34 to
77%). Therefore, MODS-PZA could be comparable to the “direct MGIT-PZA” method.
Median turnaround time of MODS-PZA were 10 and 12 days for PZA-sensitive isolates
(range, 5 to 24 days) and PZA-resistant isolates (range, 5 to 21 days), respectively; the
traditional MGIT-PZA reports a similar turnaround time ranging from 4 to 21 days (71).
It is important to mention that it remains vital to define the exact mechanism of
action of PZA in order to develop the most suitable susceptibility test for this drug,
which is considered the pivot in most current and future treatments. More data are
needed to increase our understanding of the synergy between different factors that can
enhance or reduce PZA activity under controlled in vitro conditions.
This is the first time that MODS culture has been adapted to evaluate PZA suscep-
tibility directly from sputum samples, obtaining a relatively inexpensive, simple, and
fast phenotypic DST. Currently, the implementation of any MODS based DSTs (such as
MODS-PZA) will have limitations related to laboratory infrastructure (MODS requires
biosafety level 2 facilities) (72), equipment acquisition (inverted microscope), and
personnel training in the interpretation of results. However, some advantages of the
MODS test should be highlighted. Compared to other commercial cultures or LPA-
based assays, MODS is less expensive (approximately U.S. $4 to $5 compared to U.S. $15
to $56, not considering any additional equipment) (73, 74). Although there is no
considerable cost difference compared to gene sequencing (US $8 to $12), in limited-
resource countries this procedure is usually outsourced, which implies an additional
and expensive shipping service (28). Regarding the infrastructure and equipment
implementation, every phenotypic DST has similar minimum requirements with the
exception of automatized tests (i.e., MGIT-PZA) which increase the total cost of the
assay due to the acquisition of the specific instrument. Although molecular tests (such
as LPA-based assays) may not require additional expensive instrumentation, they face
an important downside since not all pncA mutations have been reported and associ-
ated with PZA resistance (26, 27). Consequently, growth-based tests are still considered
the standard test (or at least a complementary test) for PZA susceptibility determination
(27, 39).
Recently, our group have reported an adaptation of the classic Wayne test on MODS
culture directly from sputum samples (75). This test permits an indirect determination
of PZA resistance by the detection of POA produced at pH 7.0 (i.e., with a sensitivity and
specificity of 92.7 and 99.3%, respectively) without the necessity for a primary culture.
However, one critical point of this test is the addition of PZA and ferrous ammonium
sulfate. For this, PZA is added after M. tuberculosis growth for an average of 10 days and
then, after three more incubation days, ferrous ammonium sulfate is added in order to
determine PZA susceptibility phenotype. As a result, the culture plate must be opened
twice when M. tuberculosis has just shown growth. This means that the risk of cross
contamination or culture spillover could increase if technicians do not work very
carefully. Thus, MODS-PZA is an alternative direct phenotypic DST which does not
require the addition of any reagent or the manipulation of the plate, other than for
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microscopic evaluation (i.e., the culture plate is never opened after the sputum sample
inoculation).
In spite of the sensitivity and specificity values achieved in this study, more work is
needed to evaluate the effect of other stress factors on MODS-PZA, since adjusting for
these may enable a further increase in its accuracy. The final goal is the development
of a complete, reliable, fast, and low-cost PZA susceptibility assay that could reduce the
rate of nondiagnosed PZA resistance cases, especially in low-setting countries where TB
is still an endemic disease.
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